Rusan Pharma Ltd is one of the few Indian companies that offer a one-stop-shop solution for treating various forms of addictions such as drugs, alcohol and smoking. It is also well known for its pain management products that address the entire spectrum of pain from mild to severe.
The company recently launched a state-of-the-art R&D centre ‘Navin Saxena Research & Technology’(NSRT), Clinical research organization – ‘Quest Care’ and a specialised manufacturing unit for transdermal patches at Kandla Special Economic Zone(SEZ) in Gujarat. The facility, owned by parent company Rusan Pharma Ltd, is the only one in the country to manufacture Nicotine transdermal patches in India. Set up in alignment with the PM’s ‘Make in India’ initiative, it is expected go a long way in making the Kandla SEZ vibrant and investor-friendly. The Pharma company has invested Rs 100 crore for the Research and Development (R&D) Centre.
The new establishment at Kandla houses three subsidiaries, namely the NSRT Centre, Quest Care which is the company’s clinical research organisation and Rusan’s dedicated Transdermal Patch Facility. Together, these three units will handle the myriad aspects of addiction and pain management drug manufacture and export as a part of their portfolio, including research and innovation, licensing, IPR, patenting, quality assurance. They offer immense employment opportunities not only to the local population but also to highly qualified scientists from India and abroad.
NSRT is a dedicated R&D facility that has state-of-the-art technology and equipment. Research at NSRT will focus on pain, addiction, CNS and orphan diseases, drug delivery and platform technologies. It has been set up with a vision to develop, register and license its new products to third parties. It also aims to undertake contract research and joint development projects.
Rusan group companies together have a current turnover of Rs 300 crore and intend to grow to Rs 600 crore in 2018. Being the first Indian company to do research on addiction and few orphan disease, they intend to expand their new facility with an investment of Rs 100 crore in next year.
Dr. Navin Saxena, Chairman & Founder of Rusan Pharma Ltd, said, “With our continuous efforts and innovation we are proud to announce the biggest government & private Indian company deal between Brazil Health Ministry & Rusan Pharma Ltd for USD 20 million per annum for their program for smoking cessation.”
Innovation is key for success. In the present economic climate investor want something relevant to today’s needs. Transdermal patches, the first to be manufactured indigenously by Rusan in India, fall in that niche. “This facility is the answer to the hunt for new research and medicines by global investors. We invite them to visit us and see it for themselves,” Dr Saxena added.
Kunal Saxena, Managing Director of Rusan Pharma Ltd, “Rusan and NSRT are dedicated to develop and deliver innovative products to the patients. And we are the largest and reputed suppliers of life saving drugs (Buprenorphine, Methadone and anti-TB drugs) to UNODC / UNOPS / Global Fund, MoH – Russia, CIS, South Africa, Kenya, Mauritius, Nepal, and Myanmar.”